Rigel Pharma (RIGL) Announces Completion of Fostamatinib FIT Phase 3 Enrollment
Tweet Send to a Friend
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) announced it has completed enrollment for both studies in the FIT Phase 3 clinical program ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
